🇺🇸 cisplatinum in United States
123 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 123
Most-reported reactions
- Leukopenia — 33 reports (26.83%)
- Hypoacusis — 16 reports (13.01%)
- Neutropenia — 14 reports (11.38%)
- Off Label Use — 12 reports (9.76%)
- Sepsis — 9 reports (7.32%)
- Toxicity To Various Agents — 9 reports (7.32%)
- Diarrhoea — 8 reports (6.5%)
- Infection — 8 reports (6.5%)
- Anaemia — 7 reports (5.69%)
- Death — 7 reports (5.69%)
Other Other approved in United States
Frequently asked questions
Is cisplatinum approved in United States?
cisplatinum does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for cisplatinum in United States?
The Netherlands Cancer Institute is the originator. The local marketing authorisation holder may differ — check the official source linked above.